JamesAllisonMDFAAP

PubMed

• 22 citations
  Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.
  Matthew I. Campbell, Surena F. Matin, Alda L. Tam, Rahul A. Sheth, Kamran Ahrar, Rebecca S. S. Tidwell, Priya Rao, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir,...> ;Nature Communications. 2021 Nov 4
• Checkpoint Blockade + Chemotherapy: the Right Combination for AML?
  Spencer C. Wei, James J. Mancuso, Naval Daver, James P. Allison> ;Blood Cancer Discovery. 2021 Nov 1
• 37 citations
  Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
  Hussein A. Abbas, Dapeng Hao, Katarzyna Tomczak, Praveen Barrodia, Jin Seon Im, Patrick K. Reville, Zoe Alaniz, Wei Wang, Ruiping Wang, Feng Wang, Gheath Alatrash, Koi...> ;Nature Communications. 2021 Oct 18
• 24 citations
  Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrop...
  Sumit K. Subudhi, Bilal A. Siddiqui, Ana Aparicio, Shalini S. Yadav, Sreyashi Basu, Hong Chen, Sonali Jindal, Rebecca S. S. Tidwell, Ashwin Varma, Christopher J. Logot...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
• 3 citations
  Rising Use of Multitarget Stool DNA Testing for Colorectal Cancer.
  Richard M. Hoffman, Barcey T. Levy, James E. Allison> ;JAMA Network Open. 2021 Sep 1
• 39 citations
  Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
  Tina Cascone, Annikka Weissferdt, Myrna C.B. Godoy, William N. William, Cheuk Hong Leung, Heather Lin, Sreyashi Basu, Shalini S. Yadav, Apar Pataer, Kyle G. Mitchell, ...> ;Nature Communications. 2021 Aug 19
• 43 citations
  LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy
  Naveen Sharma, Oluwatomisin T. Atolagbe, Zhongqi Ge, James P. Allison> ;The Journal of Experimental Medicine. 2021 Jul 5
• 51 citations
  Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
  Renata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, M. Laura Rubin, Ying Yuan, Diana Bell, Adel K. El-Naggar, Jason M. Johnson, William H. Morrison, David I. Rosen...> ;Clinical Cancer Research. 2021 Jun 29
• 14 citations
  Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
  Meenal Sinha, Li Zhang, Sumit K. Subudhi, Brandon Chen, Jaqueline Marquez, E Liu, Kate Allaire, Alexander Cheung, Sharon Ng, Christopher Nguyen, Terence W. Friedlander...> ;Journal for Immunotherapy of Cancer. 2021 May 1
• 16 citations
  First-in-human phase I study of ABBV-085, an antibody–drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors
  George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, Alexander I. Spira, Vivek Subbiah, Louie Naumovski, Chris Chen, Hua Fang, Dominic W. Lai, Huib...> ;Clinical Cancer Research. 2021 Apr 5
• 271 citations
  The Next Decade of Immune Checkpoint Therapy.
  Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, Shalini S. Yadav, Sumit K. Subudhi, Jianjun Gao, Sangeeta Goswami, James P. Allison> ;Cancer Discovery. 2021 Apr 1
• 119 citations
  A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention
  Spencer C. Wei, Wouter C. Meijers, Margaret L Axelrod, Nana Ama A.S. Anang, Elles M. Screever, Elizabeth Wescott, Douglas B. Johnson, Elizabeth M. Whitley, Lorenz H. L...> ;Cancer Discovery. 2021 Mar 1
• 311 citations
  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
  Tina Cascone, William N. William, Annikka Weissferdt, Cheuk Hong Leung, Heather Lin, Apar Pataer, Myrna C.B. Godoy, Brett W. Carter, Lorenzo Federico, Alexandre Reuben...> ;Nature Medicine. 2021 Feb 18
• 34 citations
  Frontiers in cancer immunotherapy—a symposium report
  Jennifer Cable, Benjamin D. Greenbaum, Dana Pe'er, Catherine M. Bollard, Sofía Bruni, Matthew E. Griffin, James P. Allison, Catherine J. Wu, Sumit K. Subudhi, Elaine R...> ;Annals of the New York Academy of Sciences. 2021 Apr 1
• 159 citations
  Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
  Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene O. Siefker-Radtke, Matthew T. Campbell, Rebecca S. S. Tidwell, Charles C. Guo, Ashish M. Kamat, Surena F. Matin, John C...> ;Nature Medicine. 2020 Oct 12
• 95 citations
  Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
  Kathleen M. McAndrews, Dara P. Dowlatshahi, Jianli Dai, Lisa M. Becker, Janine Hensel, Laura M. Snowden, Jennifer M. Leveille, Michael R. Brunner, Kylie W. Holden, Nik...> ;JCI Insight. 2020 Sep 17
• 70 citations
  ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.
  Sangeeta Goswami, Yulong Chen, Swetha Anandhan, Péter Szabó, Sreyashi Basu, Jorge Blando, Wenbin Liu, Jan Zhang, Seanu Meena Natarajan, Liangwen Xiong, Baoxiang Guan, ...> ;Science Translational Medicine. 2020 Jun 17
• 15 citations
  Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
  Akash Mitra, Miles C. Andrews, Whijae Roh, Marianna Petaccia De Macedo, Courtney W. Hudgens, Fernando Carapeto, Shailbala Singh, Alexandre Reuben, Feng Wang, Xizeng Ma...> ;Nature Communications. 2020 Apr 15
• 89 citations
  Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
  John de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, Kathy Hunter, Be Lian Pei, Barbara O’Brien, Shiao Pei Weathers, Monica Loghin, Carlos Kamiya Matsouka, W. K. Al...> ;Neuro-Oncology. 2020 Apr 15
• 94 citations
  Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.
  Sumit K. Subudhi, Luis M Vence, Hao Zhao, Jorge Blando, Shalini S. Yadav, Qing Xiong, Alexandre Reuben, Ana Aparicio, Paul G. Corn, Brian F. Chapin, Louis L. Pisters, ...> ;Science Translational Medicine. 2020 Apr 1
• 222 citations
  Dissecting the mechanisms of immune checkpoint therapy
  Padmanee Sharma, James P. Allison> ;Nature Reviews. Immunology. 2020 Feb 1
• 120 citations
  Comprehensive T cell repertoire characterization of non-small cell lung cancer
  Alexandre Reuben, Jiexin Zhang, Shin Heng Chiou, Rachel M. Gittelman, Jun Li, Won-Chul Lee, Junya Fujimoto, Carmen Behrens, Xiaoke Liu, Feng Wang, Kelly Quek, Chunlin ...> ;Nature Communications. 2020 Jan 30
• 209 citations
  Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
  Sangeeta Goswami, Thomas Walle, Andrew E. Cornish, Sreyashi Basu, Swetha Anandhan, Irina Fernandez, Luis M Vence, Jorge Blando, Hao Zhao, Shalini S. Yadav, Martina Ott...> ;Nature Medicine. 2020 Jan 1
• 35 citations
  High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer
  Erminia Massarelli, Vincent K. Lam, Edwin R. Parra, Jaime Rodriguez-Canales, Carmen Behrens, Lixia Diao, Jing Wang, Jorge Blando, Lauren Averett Byers, Niranjan Yanama...> ;Journal for Immunotherapy of Cancer. 2019 Dec 16
• 186 citations
  Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
  Spencer C. Wei, Nana Ama A.S. Anang, Roshan Sharma, Miles C. Andrews, Alexandre Reuben, Jacob H. Levine, Alexandria P. Cogdill, James J. Mancuso, Jennifer A. Wargo, Da...> ;Proceedings of the National Academy of Sciences of the United States of America. 2019 Nov 5
• Join now to see all